ADENO-ASSOCIATED VIRUS TYPE 6 IS RETROGRADELY TRANSPORTED IN THE NON-HUMAN PRIMATE BRAIN
暂无分享,去创建一个
Krystof S. Bankiewicz | Phillip Pivirotto | John Bringas | K. Bankiewicz | J. Bringas | A. Kells | John Forsayeth | J. Forsayeth | Lluis Samaranch | Adrian P. Kells | Waldy San Sebastian | Gregory Heller | W. S. Sebastián | P. Pivirotto | L. Samaranch | Gregory Heller
[1] T. Powell,et al. The cortico-striate projection in the monkey. , 1970, Brain : a journal of neurology.
[2] M. Sands,et al. Intravitreal Gene Therapy Reduces Lysosomal Storage in Specific Areas of the CNS in Mucopolysaccharidosis VII Mice , 2003, The Journal of Neuroscience.
[3] K. Bankiewicz,et al. Guided delivery of adeno-associated viral vectors into the primate brain. , 2012, Advanced drug delivery reviews.
[4] Chunling Tang,et al. Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector. , 2003, Current opinion in drug discovery & development.
[5] D. Young,et al. Nucleic Acid-Based Therapy Approaches for Huntington's Disease , 2012, Neurology research international.
[6] D. Yin,et al. Efficient gene therapy-based method for the delivery of therapeutics to primate cortex , 2009, Proceedings of the National Academy of Sciences.
[7] P. Goldman-Rakic,et al. Longitudinal topography and interdigitation of corticostriatal projections in the rhesus monkey , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[8] J. Cummings,et al. Huntington's disease. , 1997, The Psychiatric clinics of North America.
[9] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[10] Gabriele Mittermeyer,et al. Axonal transport of adeno-associated viral vectors is serotype-dependent , 2012, Gene Therapy.
[11] C. Ross,et al. Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.
[12] J. F. Wright,et al. Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] Paul S Larson,et al. Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[14] Ryuta Saito,et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. , 2005, Journal of neurosurgery.
[15] M. Fiandaca,et al. Image-guided convection-enhanced delivery platform in the treatment of neurological diseases , 2011, Neurotherapeutics.
[16] P F Morrison,et al. Convection-enhanced delivery of macromolecules in the brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[17] K. Bankiewicz,et al. Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[18] B. Davidson,et al. Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. , 2008, Human gene therapy.
[19] Yoji Yamashita,et al. The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[20] J. Bringas,et al. Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. , 2006, Human gene therapy.
[21] L. Villarreal,et al. Adeno-associated virus vectors can be efficiently produced without helper virus , 1998, Gene Therapy.
[22] N. L. Chamberlin,et al. Recombinant adeno-associated virus vector: use for transgene expression and anterograde tract tracing in the CNS , 1998, Brain Research.